Skip to main content
Erschienen in: PharmacoEconomics 5/2000

01.05.2000 | Consensus Conference Papers

Testing the Validity of Cost-Effectiveness Models

verfasst von: Mr Chris McCabe, Simon Dixon

Erschienen in: PharmacoEconomics | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

A growing body of recent work has identified several problems with economic evaluations undertaken alongside controlled trials that can have potentially serious impacts on the ability of decision makers to draw valid conclusions. At the same time, the use of cost-effectiveness models has been drawn into question, due to the alleged arbitrary nature of their construction. This has led researchers to try and identify ways of improving the quality of cost-effectiveness models through identifying ‘best practice’, producing guidelines for peer review and identifying tests of validity.
This paper investigates the issue of testing the validity of cost-effectiveness models or, perhaps more appropriately, whether it is possible to objectively measure the quality of a cost-effectiveness model. A review of the literature shows that there is much confusion over the different aspects of modelling that should be assessed in respect to model quality, and how this should be done.
We develop a framework for assessing model quality in terms of: (i) the structure of the model; (ii) the inputs of the model; (iii) the results of the model; and (iv) the value of the model to the decision maker. Quality assessment is investigated within this framework, and it is argued that it is doubtful that a set of objective tests of validity will ever be produced, or indeed that such an approach would be desirable. The lack of any clearly definable and objective tests of validity means that the other parts of the evaluation process need to be given greater emphasis. Quality assurance forms a small part of a broader process and is best implemented in the form of good practice guidelines. A set of key guidelines are presented.
Fußnoten
1
Some aspects of economic evaluation models may be tested in the conventional way. For example, regression analysis can be used to extrapolate the results of trials (e.g. estimating the reduction in mortality following a reduction in cigarette smoking).
 
2
Scales for ranking the methodological quality of a study have been proposed by several researchers. For example, the US Task Force on Preventative Health Care ranked studies in the following order: (i) meta-analyses; (ii) randomised controlled trials; (iii) non-randomised controlled trials; (iv) quasiexperimental studies; (v) descriptive studies; and (vi) opinion.
 
Literatur
1.
Zurück zum Zitat Kassirer JP, Angell M. The journal’s policy on cost effectiveness analyses [editorial]. N Engl J Med 1994; 331 (10): 669–70PubMedCrossRef Kassirer JP, Angell M. The journal’s policy on cost effectiveness analyses [editorial]. N Engl J Med 1994; 331 (10): 669–70PubMedCrossRef
2.
Zurück zum Zitat O’Brien B. Economic evaluation of pharmaceuticals: Frankenstein’s monster or vampire of trials? Med Care 1996; 34 (12): DS99–108 O’Brien B. Economic evaluation of pharmaceuticals: Frankenstein’s monster or vampire of trials? Med Care 1996; 34 (12): DS99–108
3.
Zurück zum Zitat Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984; 5: 115–28PubMedCrossRef Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984; 5: 115–28PubMedCrossRef
4.
Zurück zum Zitat Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561–73PubMedCrossRef Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561–73PubMedCrossRef
5.
Zurück zum Zitat Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomised controlled trials. Med Care 1992; 30 : 231–43PubMedCrossRef Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomised controlled trials. Med Care 1992; 30 : 231–43PubMedCrossRef
6.
Zurück zum Zitat Morris J, Goddard M. Economic evaluation and quality of life assessments in cancer clinical trials: the CHART trial. Eur J Cancer 1993; 5: 766–70CrossRef Morris J, Goddard M. Economic evaluation and quality of life assessments in cancer clinical trials: the CHART trial. Eur J Cancer 1993; 5: 766–70CrossRef
7.
Zurück zum Zitat Bonsel GJ, Rutten FFH, Uyl-de Groot CA. Economic evaluation alongside cancer trials: methodological and practical aspects. Eur J Cancer 1993; 29A: S10–4PubMedCrossRef Bonsel GJ, Rutten FFH, Uyl-de Groot CA. Economic evaluation alongside cancer trials: methodological and practical aspects. Eur J Cancer 1993; 29A: S10–4PubMedCrossRef
8.
Zurück zum Zitat Drummond MF. Economic analysis alongside clinical trials: problems and potential. J Rheumatol 1995; 22: 1403–7PubMed Drummond MF. Economic analysis alongside clinical trials: problems and potential. J Rheumatol 1995; 22: 1403–7PubMed
9.
Zurück zum Zitat Powe NE, Griffiths RI. The clinical-economic trial: promise, problems, and challenges. Control Clin Trials 1995; 16: 377–94PubMedCrossRef Powe NE, Griffiths RI. The clinical-economic trial: promise, problems, and challenges. Control Clin Trials 1995; 16: 377–94PubMedCrossRef
10.
Zurück zum Zitat Mauskopf J, Schulman K, Bell L, et al. A strategy for collecting pharmacologic data during phase II/III clinical trials. Pharmacoeconomics 1996; 9: 264–77PubMedCrossRef Mauskopf J, Schulman K, Bell L, et al. A strategy for collecting pharmacologic data during phase II/III clinical trials. Pharmacoeconomics 1996; 9: 264–77PubMedCrossRef
11.
Zurück zum Zitat Ellwein LB, Drummond MF. Economic analysis alongside clinical trials: bias in the assessment of economic outcomes. Int J Technol Assess Health Care 1996; 12: 691–7PubMedCrossRef Ellwein LB, Drummond MF. Economic analysis alongside clinical trials: bias in the assessment of economic outcomes. Int J Technol Assess Health Care 1996; 12: 691–7PubMedCrossRef
12.
Zurück zum Zitat Rigby K, Silagy C, Crockett A. Can resource use be extracted from randomized controlled trials to calculate costs? Int J Technol Assess Health Care 1996; 12: 714–20PubMedCrossRef Rigby K, Silagy C, Crockett A. Can resource use be extracted from randomized controlled trials to calculate costs? Int J Technol Assess Health Care 1996; 12: 714–20PubMedCrossRef
13.
Zurück zum Zitat Rittenhouse BE. Exorcising protocol-induced spirits: making the clinical trial relevant for economists. Med Decis Making 1997; 17: 331–9PubMedCrossRef Rittenhouse BE. Exorcising protocol-induced spirits: making the clinical trial relevant for economists. Med Decis Making 1997; 17: 331–9PubMedCrossRef
14.
Zurück zum Zitat Sheldon T. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5 (1): 1–11PubMedCrossRef Sheldon T. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5 (1): 1–11PubMedCrossRef
15.
Zurück zum Zitat Eddy D. Technology assessment: the role of mathematical modelling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144–60 Eddy D. Technology assessment: the role of mathematical modelling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144–60
16.
Zurück zum Zitat Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6 (3): 217–28PubMedCrossRef Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6 (3): 217–28PubMedCrossRef
17.
Zurück zum Zitat Mandelblatt JS, Fryback DG, Weinstein MC, et al. Assessing the effectiveness of health interventions. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness analysis in health and medicine. New York (NY): Oxford University Press, 1996: 135–64 Mandelblatt JS, Fryback DG, Weinstein MC, et al. Assessing the effectiveness of health interventions. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness analysis in health and medicine. New York (NY): Oxford University Press, 1996: 135–64
18.
Zurück zum Zitat Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Med Care 1994; 32 (7): JS52–64 Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Med Care 1994; 32 (7): JS52–64
19.
Zurück zum Zitat Ellis J, Mulligan I, Rowe J, et al. Inpatient general medicine is evidence based. Lancet 1995 Aug 12; 346 (8972): 407–10PubMedCrossRef Ellis J, Mulligan I, Rowe J, et al. Inpatient general medicine is evidence based. Lancet 1995 Aug 12; 346 (8972): 407–10PubMedCrossRef
20.
Zurück zum Zitat Morris S, McGuire A, Caro J, et al. Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature. J Health Serv Res Policy 1997; 2: 231–50PubMed Morris S, McGuire A, Caro J, et al. Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature. J Health Serv Res Policy 1997; 2: 231–50PubMed
21.
Zurück zum Zitat Deverill M, Brazier J, Green C, et al. The use of QALY and non-QALY measures of health related quality of life: assessing the state of the art. Pharmacoeconomics 1998; 13 (4): 411–20PubMedCrossRef Deverill M, Brazier J, Green C, et al. The use of QALY and non-QALY measures of health related quality of life: assessing the state of the art. Pharmacoeconomics 1998; 13 (4): 411–20PubMedCrossRef
22.
Zurück zum Zitat Dolan P. Valuing health related quality of life: issues and controversies. Pharmacoeconomics 1999; 15 (2): 119–27PubMedCrossRef Dolan P. Valuing health related quality of life: issues and controversies. Pharmacoeconomics 1999; 15 (2): 119–27PubMedCrossRef
23.
Zurück zum Zitat Rittenhouse B. Use of models in economic evaluations of medicines and other technologies. London: Office of Health Economics, 1996 Rittenhouse B. Use of models in economic evaluations of medicines and other technologies. London: Office of Health Economics, 1996
24.
Zurück zum Zitat Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1 (2): 131–47PubMedCrossRef Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1 (2): 131–47PubMedCrossRef
25.
Zurück zum Zitat Halpern MT, McKenna M, Hutton J. Modeling in economic evaluation: an unavoidable fact of life [letter]. Health Econ 1998; 7 (8): 741–2PubMedCrossRef Halpern MT, McKenna M, Hutton J. Modeling in economic evaluation: an unavoidable fact of life [letter]. Health Econ 1998; 7 (8): 741–2PubMedCrossRef
26.
Zurück zum Zitat Nuijten MJC. The selection of data sources for use in modelling studies. Pharmacoeconomics 1998; 13 (3): 305–16PubMedCrossRef Nuijten MJC. The selection of data sources for use in modelling studies. Pharmacoeconomics 1998; 13 (3): 305–16PubMedCrossRef
27.
Zurück zum Zitat Tosteson AHA, Rosenthall DI, Melton LJ, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603PubMed Tosteson AHA, Rosenthall DI, Melton LJ, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603PubMed
28.
Zurück zum Zitat Sculpher M, Michaels J, McKenna M, et al. A cost utility analysis of laser-angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12 (1): 104–25PubMedCrossRef Sculpher M, Michaels J, McKenna M, et al. A cost utility analysis of laser-angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12 (1): 104–25PubMedCrossRef
29.
Zurück zum Zitat Schulpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997; 2 (1): 26–30 Schulpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997; 2 (1): 26–30
Metadaten
Titel
Testing the Validity of Cost-Effectiveness Models
verfasst von
Mr Chris McCabe
Simon Dixon
Publikationsdatum
01.05.2000
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 5/2000
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200017050-00007

Weitere Artikel der Ausgabe 5/2000

PharmacoEconomics 5/2000 Zur Ausgabe

Consensus Conference Papers

Modelling in Health Economic Evaluation

Adis Pharmacoeconomic Drug Evaluation

Mirtazapine